A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001)
Status:
Recruiting
Trial end date:
2023-09-15
Target enrollment:
Participant gender:
Summary
This study will evaluate the effect of each dose of MK-3655 versus placebo on the percentage
of individuals with NASH resolution without worsening of fibrosis after 52 weeks. The primary
hypothesis of the study is that at least 1 dose of MK-3655 is superior to placebo with
respect to the percentage of individuals with NASH resolution without worsening of fibrosis
after 52 weeks.